Pirtobrutinib and BTK Inhibitors in the CLL Treatment Landscape
Pharmacy Times,
Image credit: jarun011 | stock.adobe.com Précis This review discusses the prevalence, mechanisms of development, and evolving…
Image credit: jarun011 | stock.adobe.com Précis This review discusses the prevalence, mechanisms of development, and evolving…
Treatment with ibrutinib in patients with chronic lymphocytic leukemia was linked with increased risk of cardiovascular adverse…
Patients now have multiple options, including continuous therapy with BTK inhibitors and fixed-duration therapy with venetoclax-b…
Atrial fibrillation, bleeding, infection, and other adverse events may occur with this therapy.